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Achieving Better Care in Pennsylvania
by Allowing Pharmacists to Practice
Pharmacy
Travis J. Murray*
ABSTRACT
Traditionally, state legislatures implemented Prescription
Drug Monitoring Programs (“PDMPs”) to assist prescribers,
pharmacists, and law enforcement in identifying patients likely to
misuse, abuse, or divert controlled substances. PDMP databases
contain a catalog of a patient’s recent controlled substances that
pharmacies have filled, including the date, location, the quantity
of medication filled, and the prescribing health care provider.
Prescribers in Pennsylvania have a duty to query the PDMP
before prescribing controlled substances in most clinical settings.
Pharmacists have a similar duty in Pennsylvania to dispense safe
and effective medication therapy to patients and to screen patients for potential signs of misuse, abuse, or diversion.
However, Pennsylvania’s most recent PDMP laws, The
Achieving Better Care by Monitoring All Prescriptions Program
Act (“ABC-MAP” Act) and the Safe Emergency Prescribing Act
(“SEP” Act), restrict a pharmacist’s access to the PDMP in the
hospital’s emergency room. Pharmacists need PDMP access to
screen for drug-drug interactions and for potential misuse, abuse,
or diversion. Pharmacists’ need for this tool is especially great in
light of the current drug epidemic.
As licensed medication experts, pharmacists have the training and expertise to identify patients at risk for chemical dependence and addiction. However, a pharmacist who accesses the
PDMP for a patient who has been prescribed a controlled substance without authorization under these laws may face criminal,
civil, and administrative liability that could affect his ability to
maintain a license and practice pharmacy.
This Comment first explains the unique standard of care that
a Pennsylvania pharmacist owes to his or her patients and the
* J.D. Candidate, Pennsylvania State University Dickinson Law, 2021. This comment is dedicated in loving memory of his grandfather, Gene R. Tagle.
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interprofessional relationship between prescribers and pharmacists. This Comment then will argue that pharmacists, as essential health care providers, require PDMP access to improve
patient outcomes, especially in the emergency room setting.
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I. INTRODUCTION
Imagine a young woman afflicted with breast cancer who lives
in the Commonwealth of Pennsylvania with her husband and chil-
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dren.1 The oncologist is optimistic about her prognosis with radiation and adjuvant chemotherapy.2 The oncologist prescribes her
extended-release morphine to ameliorate the pain associated with
treatment. Unbeknownst to her husband, the young woman also
sees a psychiatrist who prescribes her alprazolam three times daily
as needed for anxiety associated with the existential stress of her
cancer. The young woman also develops a cough, possibly from a
chemotherapy-induced weakened immune system, and receives a
prescription for guaifenesin and hydrocodone from an urgent care
physician. The next day, her husband finds her unconscious, and an
ambulance rushes her to the emergency room. The young woman
cannot void to produce a urine drug screen, and she does not adequately respond to naloxone, the reversal agent for opioids. She
slips into a medically induced coma before dying. The combination
of morphine, alprazolam, and hydrocodone is a lethal cocktail with
black-boxed warnings from the United States Food and Drug Administration (FDA) that any reasonable pharmacist would be able
to identify and alert to her prescribers.3 The young woman may
have survived had she received flumazenil, the reversal agent for
alprazolam, in combination with naloxone.4
Had the young woman’s pharmacist been able to access the
Prescription Drug Monitoring Program (“PDMP”), a database
which is capable of providing a history of controlled substances filled by pharmacies, the system may have alerted pharmacists and
prescribers that she was experiencing this life-threatening drug interaction.5 However, Pennsylvania state law restricts pharmacists
from accessing this database in certain settings, such as emergency

1. This Comment uses a fictional scenario to demonstrate how the law that
governs Pennsylvania prescribing and dispensing laws in emergency rooms between June 30, 2015, and November 10, 2020, could apply in a factual situation.
2. See Adjuvant Therapy, NATIONAL CANCER INST. DICTIONARY OF CANCER
TERMS, https://bit.ly/2J1Fbo7 [https://perma.cc/K2RV-MAP7] (last visited Dec. 4,,
2020) (defining “adjuvant therapy”).
3. See Press Release, FDA Requires Strong Warnings for Opioid Analgesics,
Prescription Opioid Cough Products, and Benzodiazepine Labeling Related to Serious Risk and Death from Combined Use, U.S. Food & Drug Admin. (Aug. 31,
2016), https://bit.ly/2SfFpun [https://perma.cc/EHT6-P4K4] (warning against the
combination of benzodiazepines and opioids due to the increased risk of central
nervous system depression and toxicity).
4. See Genentech, Romazicon® Prescribing Information, lines 250–54 https://
bit.ly/2pYQww2 [https://perma.cc/JLM4-3BGK] (last revised Apr. 2010) (explaining that flumazenil is indicated for the management of benzodiazepine overdose).
5. See Achieving Better Care by Monitoring All Prescriptions Program Act,
35 PA. STAT. AND CONS. STAT. § 872.2 (West 2015).
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rooms, inpatient hospital admissions, and certain community pharmacy situations.6
The PDMP is a powerful resource for health care professionals. To understand why the PDMP is so powerful, it is important to
contextualize the interdisciplinary process of verifying and dispensing prescriptions. This, in turn, requires an overview of the pharmacist’s role in modern American health care. Part II will provide
the background of the pharmacy profession, from ancient history to
modern-day American pharmacy science and practice.7 Part II will
also discuss the regulation of pharmacists, particularly in Pennsylvania, under federal and state law as well as under Pennsylvania’s Board of Pharmacy.8 The next section of Part II will
discuss the regulation of pharmaceuticals in the United States, including opioids and other controlled substances.9 This section will
also provide an overview of prescribing and dispensing guidelines
for controlled substances in light of the current opioid epidemic.10
The final section of Part II will cover the special duty of care that
pharmacists owe to patients and, subsequently, how pharmacists
can protect themselves from professional malpractice in Pennsylvania.11 Specifically, this section will introduce the conflicts that
arise between a traditional pharmacist’s duty of care and how this
duty is modified under key pieces of Pennsylvania legislation, the
Achieving Better Care by Monitoring All Prescriptions Act
(“ABC-MAP Act”) and the Safe Emergency Prescribing Act
(“SEP Act”).12 Part III will analyze how the ABC-MAP Act and
the SEP Act have placed Pennsylvania pharmacists in a position
that makes it difficult for them to faithfully execute their duty of
care to patients without violating the law.13 These laws appear to
directly conflict with clinical practice guidelines, the formal training

6. See 35 PA. STAT. AND CONS. STAT. § 873.5 (West 2017) (requiring
prescribers query the PDMP to determine if a patient is being treated with an
opioid drug product by another prescriber, except in emergency room treatment,
even if the pharmacist has not queried the system). See also Act of Nov. 2, 2016,
2016 Pa. Laws 124 (amending Achieving Better Care by Monitoring All Prescriptions Program Act, 2014 Pa. Laws 191 (permitting a prescriber to not query the
PDMP if a patient is admitted to the hospital or remains in observation status)).
7. See infra Part II.A.
8. See infra Part II.B.
9. See infra Part II.B.
10. See infra Part II.B.
11. See infra Part II.D.
12. See infra Part II.D.
13. See infra Part III.
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and education of pharmacists, and the oath of the pharmacy
profession.14
II. BACKGROUND
A. Historical Background of the Pharmacy Profession
1. Ancient World to the Middle Ages
Modern-day pharmacists rank as one of the most trusted
groups of professionals.15 While the roots of the science and practice of American pharmacy directly descended from European
apothecaries, the profession is one that was present in virtually
every civilization throughout history.16 Ancient apothecaries appear to have existed in antiquity, as recorded history identifies early
pharmacist-like persons in Babylon and China’s Yellow River Valley civilizations who used herbal extracts to treat common maladies
in 2600 and 2000 B.C., respectively.17 Ancient Egyptian apothecaries recorded prescriptions and detailed compounding methods in
Ebers Papyrus, a collection of hundreds of prescriptions and formulas from plants and substances from 1500 B.C.18 The Greek pharmacologist Dioscorides wrote the first substantive pharmacopeia,
which spread throughout Europe, the Middle East, and North Africa and which apothecaries used for over one thousand years.19 As
knowledge spread, apothecaries developed guilds across Europe to
train future apothecaries to compound and expand the known
pharmacopeia.20 The first semblances of pharmacies appeared on
the Arabian and Italian peninsulas during the late-Middle Ages and
the Islamic Golden Age, respectively, as apothecaries began incor14. See infra Part III.
15. See Honesty/Ethics in Professions, GALLUP, https://bit.ly/34MSxKn [https:/
/perma.cc/X898-SHTC] (last visited Dec. 4, 2020) (determining that 64 percent of
respondents rated the honesty and ethical standards of pharmacists as “very high”
or “high”).
16. See generally George B. Griffenhagen, Great Moments in Pharmacy: Development of Robert Thom Series Depicting Pharmacy’s History, 42 J. AM. PHARM.
ASSOC. 170 (2002) (describing the evolution of pharmacists across civilizations and
millennia).
17. GEORGE A. BENDER, A HISTORY OF PHARMACY IN PICTURES 5 (1965).
18. ANCIENT EGYPTIAN MEDICINE: THE PAPYRUS EBERS (Cyril P. Bryan
trans. 1930).
19. Dioscorides: Early Pharmacology, NATIONAL INSTITUTES OF HEALTH,
https://bit.ly/34hSgPv [https://perma.cc/F738-SGAC] (last visited Dec. 4, 2020). See
also KEVIN M. G. TAYLOR & GEOFFREY HARDING, PHARMACY PRACTICE 4–5
(2016); pharmacopoeia, MERRIAM-WEBSTER, https://bit.ly/2EKQVpE [https://
perma.cc/C7RC-V6M8] (last visited Dec. 4, 2020) (defining a pharmacopoeia as “a
book describing drugs, chemicals, and medicinal preparations”).
20. Apothecaries, SCIENCE MUSEUM, https://bit.ly/2pvoO9Z [https://perma.cc/
WL6U-EA2M] (last visited Dec. 4, 2020).
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porating pharmacology and toxicology to understand the physiological effects of herbs and substances.21
2. Renaissance and the Age of Enlightenment
Medicine and apothecary split into two distinct professions in
1240 A.D. in Sicily—a distinction that spread throughout Europe
and continues to this day.22 In Florence, the Guild of Apothecaries
produced an updated official pharmacopeia, Nuovo Receptario,
which became widely adopted in Western Europe.23 By the 1600s,
London apothecaries formed the Society of Apothecaries, which
aimed to train pharmacists to be skilled medication experts and to
be directly involved with contemporaneous advances in chemistry,
the new frontier for drug synthesis and discovery.24 This method of
training carried across the Atlantic and was the norm for training
pharmacists until the mid-1800s.25
3. Modern American Pharmacist
The year 1821 marked the beginning of American pharmacological education when the Philadelphia College of Pharmacy became the first American academic institute to train pharmacists in
chemistry and biology.26 The Accreditation Council for Pharmacy
Education (“ACPE”) began to accredit pharmacy schools, and the
individual state boards of pharmacy began to require graduation
from these ACPE-accredited schools to receive a pharmacist license.27 Today, pharmacy students must learn evidence-based
pharmacotherapeutics, pharmacology, and pharmaceutics and engage in extensive experiential training in homage to the early
21. David W. Tschanz, The Islamic Roots of Modern Pharmacy,
ARAMCOWORLD, May/June 2016, 19–23.
22. HASTINGS RASHDALL, THE UNIVERSITIES OF EUROPE IN THE MIDDLE
AGES 85 (1895); James J. Walsh, The Earliest Modern Law for the Regulation of the
Practice of Medicine, BULL. N.Y. ACAD. MED. 523–24 (1935). This distinction, as
will be discussed infra Part II.C., is an important one since the roles that physicians—the practice of medication—and pharmacists—the practice of pharmacy—
play in treating patients and the medication use process are consequential in both
professions needing PDMP access.
23. KEVIN M. G. TAYLOR & GEOFFREY HARDING, PHARMACY PRACTICE 6
(2016).
24. Id. at 7–8.
25. Id.
26. Krantz & Hartley, Pharmacy, BRITANNICA, https://bit.ly/2WqmvAW
[https://perma.cc/VJB4-WG79] (last visited Dec. 4, 2020); Our History, UNIVERSITY OF THE SCIENCES, https://bit.ly/2JBl91j [https://perma.cc/845Q-VL9F] (last visited Dec. 4, 2020).
27. Our History, ACCREDITATION COUNCIL FOR PHARMACY EDUC., https://
bit.ly/2qIYwB6 [https://perma.cc/9P75-BNP2] (last visited Dec. 4, 2020).
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American and English apothecary apprenticeship systems.28 The
National Association of Boards of Pharmacy (“NABP”) offers two
exams that pharmacy school graduates must pass to practice in most
states: the North American Pharmacist Licensure Examination®
(“NAPLEX®”) and the Multistate Pharmacy Jurisprudence Examination® (“MPJE®”).29 This combination of intense experiential
and didactic training allows pharmacists to provide competent
care.30
With all of the trust and confidence that society has placed in
pharmacists, and the severity of the risks inherent to pharmaceuticals, pharmacists owe a duty of care to patients, which requires
them to rely on as much information as possible to make the best
clinical decisions when dispensing and compounding medications.31
Pharmacists have been integral in the development of medicinal
botany, pharmacology, toxicology, and chemistry for millennia,
which have advanced society and public health.32 For the profession to survive and provide competent patient care, pharmacists
must continue to show the same compassion and expertise that the
world has relied upon, and they must have access to every resource
possible to effectively serve patients.33 However, as this Comment
will explain, certain laws and regulations obstruct the pharmacist’s
ability to provide safe, effective, and trustworthy care to combat
one of America’s gravest public health emergencies—the opioid epidemic. In order to understand these laws, it is important to discuss
the regulation of pharmacists and pharmaceuticals as well as the
extent of the current epidemic.
28. ACCREDITATION COUNCIL FOR PHARMACY EDUC., ACCREDITATION
STANDARDS AND KEY ELEMENTS FOR THE PROFESSIONAL PROGRAM IN PHARMACY LEADING TO THE DOCTOR OF PHARMACY DEGREE 5–9 (2015), https://bit.ly/
2Q8GXFp [https://perma.cc/X9YC-XVC7] [hereinafter Accreditation Standards].
29. Id. at preamble; MPJE, NATL. ASS’N BDS. PHARMACY, https://bit.ly/
2qEGm3L [https://perma.cc/QKC6-6MKH] (last visited Dec. 4, 2020) (requiring a
pharmacist to demonstrate competency in pharmaceutical indications, interactions,
and calculations, as well as knowledge of the laws and regulations governing pharmacy practice, respectively).
30. Accreditation Standards, supra note 28, at Preamble.
31. Riff v. Morgan Pharmacy, 508 A.2d 1247, 1251 (Pa. Super. 1986); 49 PA.
CODE § 27.18 (2019).
32. See generally Griffenhagen, supra note 16 (indicating the role of apothecaries in identifying plants and substances that could be used and compounded to
treat ailments or reverse symptoms, synthesizing pharmaceuticals using chemistry,
and becoming trusted medication and supplement experts across civilizations).
33. See Kristy Malacos, PDMPs Can Help Curb the Opioid Epidemic, PHARMACY TIMES (Nov. 20, 2019), https://bit.ly/2sVhfum [https://perma.cc/H2TGCLQ2].
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B. Regulation of Pharmaceuticals, Controlled Substances, and the
Practice of Pharmacy
1. Federal and State Law
Generally, federal law regulates pharmaceuticals, and the
states regulate the practice of pharmacy. The United States first
regulated pharmaceuticals under the Pure Food and Drug Act
(“PFDA”)34 and the Food, Drug, and Cosmetic Act (“FDCA”),35
which created the FDA.36 A pharmacist or practitioner can dispense a medication that is designated as “prescription only.”37
Apart from prescription and non-prescription medications, prescription medications can be further classified by their abuse potential using the scheduling system that the Controlled Substances Act
created.38 Schedule I through V designations indicate medications
with potential for abuse, with Schedule I being substances that
serve no “currently accepted medical use,” have a “high abuse potential,” and cannot be legally dispensed by a pharmacist. .39
Schedule I includes heroin and methamphetamine.40 Schedule II
encompasses medications with “accepted medical uses[ ] but high
abuse potential leading to psychological or physical dependence”
and includes most opioids such as oxycodone, fentanyl, and morphine.41 Further down the schedule list is Schedule IV, which includes benzodiazepines, such as Xanax®, Klonopin®, and Ativan®
.42 A medication’s schedule limits the number of refills and day
supply of medication that a pharmacist may dispense.43 State laws

34. Pure Food and Drug Act of 1906, Pub. L. No. 59-384, 34 Stat. 768.
35. Fed. Food, Drug, and Cosmetic Act, Pub. L. No. 75-717, 52 Stat. 1040
(1938).
36. Milestones in U.S. Food and Drug Law History, U.S. FOOD & DRUG ADMIN., https://bit.ly/2Nvgfnz [https://perma.cc/3U79-SXSD] (last visited Dec. 4,
2020) (regulating drugs to prevent adulteration and misbranding first appeared in
the PFDA and requiring drugs to demonstrate safety before being approved by the
FDA occurred in the FDCA).
37. 35 PA. STAT. AND CONS. STAT. § 780-113(a)(10) (West 2019).
38. See Controlled Substances Act, 21 U.S.C. § 812 (2019) (defining the federal schedule of controlled substances).
39. Schedule I Controlled Substances, 21 C.F.R. § 1308.11 (2019).
40. Id.
41. Schedule II Controlled Substances, 21 C.F.R. § 1308.12 (2019).
42. Schedule IV Controlled Substances, 21 C.F.R. § 1308.14 (2019).
43. U.S. DRUG ENF’T AGENCY, PHARMACIST’S MANUAL 62–70 (2020), https:/
/bit.ly/3kAt27G [https://perma.cc/JTL9-9NRV].
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can place heightened prescribing and dispensing requirements44 as
well as re-classify a medication’s schedule.45
2. Duty of a Pennsylvania Pharmacist
In Pennsylvania, pharmacists perform their duties in compliance with statutory law, the Board of Pharmacy regulations, common law, evidence-based education and clinical practice guidelines,
and the oath of a pharmacist.
a. Pennsylvania State Law and Administrative Law
In Pennsylvania, the Pennsylvania Pharmacy Act regulates
pharmacists.46 This Act created the Board of Pharmacy, which is
responsible for licensing Pennsylvania’s pharmacists, overseeing
disciplinary actions against them, and promulgating regulations to
which they must adhere.47 The Board can conduct its own hearings
and proceedings, and can sanction pharmacists.48 Examples of
sanctions include suspension, probation, and revocation of a pharmacist’s license.49 The Board may revoke or suspend a pharmacist’s license for incompetence, malpractice, or “the departure from,
or failure to conform to, the standards of acceptable and prevailing
pharmacy practice,” even in the absence of an actual injury occurring.50 Regarding the duty of a pharmacist,
A pharmacist may not knowingly fill or refill a prescription for a
controlled substance or nonproprietary drug of device if the
pharmacist knows or has reason to know it is for use by a person
other than the one for whom the prescription was written, or will
be otherwise diverted, abused, or misused. In addition, a pharmacist may decline to fill or refill a prescription if, in the pharmacist’s professional judgment exercised in the interest of the safety
of the patient, the pharmacist believes the prescription should
not be filled or refilled.51
44. See, e.g., 49 PA. CODE. § 27.18 (2019) (including stricter requirements for
pharmacists dispensing opioids than those required by the Federal Controlled Substances Act, 21 U.S.C. §§ 801–904 (2020) and the Poison Prevention Packaging Act
of 1970, 15 U.S.C. §§ 1471–76 (2020)).
45. See, e.g., ]35 PA. STAT. AND CONS. STAT. § 780-104 (West 2019); 49 PA.
CODE § 27.18 (2019).
46. Pennsylvania Pharmacy Act, 63 PA. STAT. AND CONS. STAT. § 390 (West
2019).
47. Id.
48. Id. §§ 390-5 to 390-7.
49. Id.
50. Id. § 390-5(a)(12).
51. 49 PA. CODE § 27.18 (West 2020).
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This standard seemingly gives latitude to a pharmacist when deciding to fill a prescription, but similar to the practice of medicine, the
pharmacy profession is subject to standards of practice within the
profession and clinical practice guidelines.52 “The purpose of the
Pharmacy Act was to ‘regulate . . . preparing drugs, and dispensing
them’ ” and to prioritize protecting the health and safety of the public.53 The Pennsylvania General Assembly created the Board of
Pharmacy, composed of licensed pharmacists, to better regulate the
profession and to stay connected with standards and challenges in
current practice.54
b. Clinical Practice Guidelines and Oath
A pharmacist cannot knowingly fill a prescription if he or she
knows or has reason to know another person will use the medication or that the person will divert, misuse, or abuse the medication.55 The pharmacist has the burden not only to determine if the
prescription will likely be safe and effective for the patient but also
to discern the legitimacy of the prescription.56 A prescription is
facially valid if it complies with the elements of a Pennsylvania prescription and is without signs of forgery and adulteration.57 A major concern for pharmacists is a practice known as “doctorshopping,” which involves a physician writing a prescription for a
patient, unaware that the patient is receiving the same or similar
medication from another doctor.58 Doctor-shopping can be a form
of diversion, misuse, and abuse, resulting in duplication of therapy,
a known drug-drug interaction that trained pharmacists know how
to avoid.59 However, determining whether the patient aims to use
the prescription for its intended legitimate purpose can be an ardu52. 63 PA. STAT. AND CONS. STAT. § 390-5(a)(12) (West 2019).
53. Riff v. Morgan Pharmacy, 508 A.2d 1247, 1251 (Pa. Super. 1986).
54. 63 PA. STAT. AND CONS. STAT. § 390 (2019).
55. 49 PA. CODE § 27.18 (2019).
56. Id. § 27.18(c); Gabriel v. Giant Eagle, Inc., 124 F. Supp. 3d 550, 564 (W.D.
Pa. 2015).
57. 49 PA. CODE §§ 27.18(b)(1)–(2), (5) (2019) (describing that prescription
label requirements for controlled substances include: name, address, telephone
number and DEA number of pharmacy, name of the patient, full directions, name
of the prescriber, serial number of prescription and date of original fill, trade or
brand name of the drug, drug strength, dosage form, and quantity dispensed);
Gabriel at 563 (quoting Forish v. Paul, 2 Pa. D. & C.4th 413, 416–17 (C.P. 1989)).
58. Randy A. Sansone & Lori A. Sansone, Doctor Shopping: A Phenomenon
of Many Themes, 9 INNOV. CLIN. NEUROSCI. 41, 41–42 (2012).
59. 49 PA. CODE § 27.18(c), 27.19(a)–(c), (f) (2019) (describing a drug-drug
interaction is when two or more drugs react with each other to cause a side effect).
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ous task.60 To use examples, a prescription is diverted if it is sold to
another person, misused if the person takes it more frequently or
crushes a tablet instead of swallowing it whole, or abused if it is
used in furtherance of chemical dependence or addictive
behavior.61
Additionally, a licensed pharmacist can use “professional judgment” when determining whether to fill a prescription.62 A pharmacist can also use professional judgment to deny a prescription or
hospital physician order from being dispensed so long as the denial
is “in the safety of interest of the patient.”63 This judgment comes
from academic training, professional standards issued by evidencebased medicine and clinical practice guidelines, and the principles
from the oath of a pharmacist.64 Pennsylvania’s legislature, like
most state legislatures, is hesitant to legislate the practices of
medicine and pharmacy. Instead, the Pennsylvania legislature defers to professional guidelines and the state licensing boards.65
Various medical groups and associations publish the aforementioned clinical practice guidelines. While these groups normally
publish their own guidelines, professional associations such as the
International Association for the Study of Pain recognize The
United States Centers for Disease Control and Prevention’s (CDC)
recommendations as the current standard of practice for the use of
opioids in severe non-cancer pain.66 In addition, Pennsylvania’s
60. Purpose of Issue of Prescription, 21 C.F.R. 1306.04 (2020); 35 PA. CONS.
STAT § 780-113(15) (West 2020).
61. Shannon M. Smith et al., Classification and Definition of Misuse, Abuse,
and Related Events in Clinical Trials: ACTTION Systemic Review and Recommendations, 152 PAIN 2287–96, Tables 1–2, 5 (2013).
62. 49 PA. CODE § 27.18(c) (2019).
63. Id.
64. 63 PA. CONS. STAT. § 390-3 (2019); Oath of A Pharmacist, AMERICAN
PHARMACISTS ASS’N, https://bit.ly/33Iga6X [https://perma.cc/NPT5-Q99Z] (last
visited Dec. 4, 2020) (including vows to “apply knowledge, experience, and skills to
the best of [one’s] ability to assure optimal outcomes for . . . patients [and to]
respect and protect all personal and health information”) [hereinafter Oath].
65. See 2016 PA. LEGIS. J. HOUSE 1447 (June 23, 2016) for a speech by Representative Pamela A. DeLissio of the Pennsylvania General Assembly (stating “[i]t
is well documented that opioid drug abuse is in Pennsylvania and affects all of our
citizens. However, whenever the legislature attempts to legislate how licensed
health-care providers practice . . . I think that is a very dangerous precedent . . . I
would not want to be personally in that emergency room or have my constituents
in that emergency room with a health-care provider having to say, ‘Gee, I wish I
could do this, but the Pennsylvania State Legislature passed this bill and tied my
hands.’ ”); Riff v. Morgan Pharmacy, 508 A.2d 1247, 1253 (Pa. Super. 1986) (determining that it is not the Court’s task “to delineate the precise bounds of a medical
professional’s responsibilities”).
66. See generally CTRS. FOR DISEASE CONTROL & PREVENTION, CDC GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN (2016); 65 MORBIDITY &
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Department of Health has its own recommendations for prescribing
opioids for non-cancer pain, dispensing opioids, and prescribing
benzodiazepines for acute anxiety and insomnia.67 A pharmacist’s
failure to adhere to the CDC and Pennsylvania’s dispensing recommendations may constitute a breach of a pharmacist’s duty and lead
to civil and administrative liability.68
c. Common Law
Civil liability can arise in malpractice actions. In Pennsylvania,
to establish a prima facie case of professional malpractice, the injured party must show the existence of a duty, a breach of that duty,
cause-in-fact, proximate cause, and actual harm.69 A pharmacist
breaches his duty for a “failure to correct improper dosage directions; failure to check on illegible prescriptions; and failure to notice a potentially lethal interaction between drugs on the face of a
prescription.”70 The standard of care is that of a “reasonably prudent pharmacist,” and a pharmacist must carry out his duties with
the degree of skill and care expected of the pharmaceutical profession as a whole.71 This duty has become muddled under Pennsylvania’s ABC-MAP Act and the SEP Act, which Section D of
Part II will discuss.72

MORTALITY WEEKLY REPORTS: RECOMMENDATIONS AND REPORTS 1, 1–50 (2016)
(describing the recommendations from the CDC for prescribing and dispensing
opioids to patients with pain safely to mitigate abuse, misuse, and diversion); Development of Clinical Practice Guidelines in the Field of Pain, INT’L ASS’N FOR
STUDY OF PAIN, https://bit.ly/32CexpR [https://perma.cc/AQB4-XPPJ] (last visited
Dec. 4, 2020).
67. See generally Prescribing Guidelines for Pennsylvania: Opioid Dispensing
Guidelines, PA. DEPT. HEALTH 1, 1–11 (Jan. 14, 2016), https://bit.ly/36nPYA4
[https://perma.cc/9HD3-KG5M] (reaffirming many of the general recommendations from the CDC explaining state-specific requirements for prescribing and dispensing opioids, such as utilizing the PDMP, screening patients for risk of opioid
misuse or diversion and referring at-risk patients to specific treatment options or
alternative pain therapies); see also Prescribing Guidelines for Pennsylvania: NonCancer Pain Guidelines, PA. DEPT. HEALTH 1, 1–11 (June 11, 2018), https://bit.ly/
36mLcmx [https://perma.cc/RW5B-WFG9]; see also Prescribing Guidelines for
Pennsylvania: Safe Prescribing Benzodiazepines for Acute Treatment of Anxiety &
Insomnia, PA. DEPT. HEALTH 1, 1–5 (May 15, 2017), https://bit.ly/34jwIlC [https://
perma.cc/D6B9-VAAJ].
68. 63 PA. CONS. STAT. § 390 5(a)(12) (West 2020).
69. See Riff, 508 A.2d at 1251.
70. Id.
71. Id. at 1250; Forish v. Paul, 2 Pa. D. & C.4th 413, 416–17 (C.P. 1989).
72. 2014 Pa. Laws 191; 2016 Pa. Laws 122.
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C. Narcotics, the Opioid Epidemic, and the Medication-Use
Process
In 2018, Pennsylvania experienced 4,491 drug-related overdose
deaths, which is a 36 percent increase from 2015 to 2018.73 The vast
majority of these overdoses are related to opioids and
benzodiazepines.74 The term “opioids” refers to the general class of
substances that are chemically related to opium and act on the muopioid receptor in the body to produce an analgesic effect.75 The
term “opiates” generally refers to naturally occurring opioids that
come from the poppy plant; whereas, newer opioids are synthetically created and tend to be more potent.76 While opioids are excellent for controlling moderate-to-severe chronic pain, severe
acute pain, and cancer-related pain, they come at a cost.77 In addition to the analgesic effects, opioids can cause euphoric effects that
can lead to misuse, chemical dependence, and addiction, which are
recognized as substance use disorders according to the Fifth Edition
of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-V).78 Roughly 21 to 29 percent of patients prescribed
opioids for chronic pain misuse them, 4 to 6 percent of those who
misuse opioid prescriptions transition to heroin, and about 80 percent of people who use heroin first misused prescription opioids.79
73. DRUG ENF’T AGENCY INTEL. PROGRAM—PHILA. FIELD DIV., DRUG-REOVERDOSE DEATHS IN PA., 2018 1, 3 (2018), https://bit.ly/36qJxfF [https://
perma.cc/598X-MCSP].
74. Id. at 2 (citing 82 percent of overdose deaths were associated with prescription and illicit opioids and 28 percent were associated with benzodiazepines).
75. Act of Nov. 2, 2016, 2016 Pa. Laws 124; 35 PA. STAT. AND CONS. STAT.
§ 780-112 (West 2019); Hasan Pathan & John Williams, Basic Opioid Pharmacology: An Update, 6 BR J. PAIN 11, 12–16 (2012) (explaining that an opioid is defined as a chemical that binds to the mu-opioid receptor in humans, resulting in
pain relief).
76. See Prescribing Guidelines for Pennsylvania: Opioid Dispensing Guidelines, PA. DEPT. HEALTH 6 (Jan. 14, 2016), https://bit.ly/36nPYA4 [https://perma.cc/
427M-7DES] (describing how synthetic opioid fentanyl administered intravenously
is roughly one hundred times more potent than the natural opioid morphine in
intravenous form).
77. See generally CTRS. FOR DISEASE CONTROL & PREVENTION, CDC GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN (2016) (describing the risks of
long durations of use or large doses of opioids for mild or non-chronic pain); 65
MORBIDITY & MORTALITY WEEKLY REPORTS: RECOMMENDATIONS AND REPORTS 1, 1–50 (2016) (highlighting the need to use opioids sparingly and appropriately for the controlling pain and to be aware of certain behaviors that may
indicate substance use disorder or diversion).
78. AMERICAN PSYCHIATRIC ASS’N, DIAGNOSTIC AND STATISTICAL MANUAL
OF MENTAL DISORDERS 541–46 (5th ed. 2013).
79. See Kevin E. Vowles et al., Rates of Opioid Misuse, Abuse, and Addiction
in Chronic Pain: A Systematic Review and Data Synthesis, 156 PAIN 569, 569–70
(2015). See also Pradip K. Muhuri et al., Associations of Nonmedical Pain Reliever
LATED
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In addition to addiction and death, opioids have many drug-drug
interactions, and opioid use disorder can lead to other health and
social complications, such as Human Immunodeficiency Virus
(HIV) and hepatitis C infections, bacteremia, endocarditis and
homelessness.80 The analgesic, euphoric, and toxic results from
opium and opium-derivatives are documented across history and
civilizations and may even predate the pharmacy practice.81
Benzodiazepines are another cause of drug-related overdose
and have a life-threatening drug-drug interaction with opioids that
can lead to respiratory depression and death.82 Pennsylvania defines a benzodiazepine as “a psychoactive drug . . . [that] works on
the central nervous system, acting selectively on gamma-aminobutyric acid type A (GABA(A)) receptors in the brain.”83
Benzodiazepines are used to treat generalized anxiety disorder,
among other indications.84 Pharmacists often dispense both opioids
and benzodiazepines, so screening a patient’s medication profile for
proper use is an essential component of the medication-use
process.85
The medication-use process is the life cycle of a medication
from a prescriber’s prescription to consumption by the patient.86
The process begins when a prescriber writes a prescription for a
patient for a legitimate medical purpose.87 If the prescription is for
Use and Initiation of Heroin Use in the United States, CBHSQ DATA REV. (August
2013); Robert G. Carlson et al., Predictors of Transition to Heroin Use Among
Initially Non-opioid Dependent Illicit Pharmaceutical Opioid Users: A Natural History Study, 160 DRUG ALCOHOL DEPENDENCE 127, 127 (2016).
80. Infectious Disease, Opioids and Injection Drug Use, CTRS. FOR DISEASE
CONTROL & PREVENTION, https://bit.ly/2NA5OAe [https://perma.cc/Q3AZ-67KX]
(last visited Dec. 4, 2020); Homeless and Housing Services Providers Confront
Opioid Overdose, SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., https://
bit.ly/2qKHjaw [https://perma.cc/JN92-ZMXX] (last visited Dec. 4, 2020).
81. LUCY INGLIS, MILK OF PARADISE: A HISTORY OF OPIUM 14–16 (2018).
82. U.S. FOOD & DRUG ADMIN., FDA News Release: FDA Requires Strong
Warnings for Opioid Analgesics, Prescription Opioid Cough Products, and
Benzodiazepine Labeling Related to Serious Risk and Death from Combined Use
(Aug. 31, 2016), https://bit.ly/38dlKQ5 [https://perma.cc/AX9T-N3G4].
83. Act of Nov. 2, 2016, 2016 Pa. Laws 124.
84. PHARMACIA & UPJOHN CO., XANAX® PRESCRIBING INFORMATION 4–5
(2016), https://bit.ly/3jAj4S8 [https://perma.cc/RM3T-Q5Z9].
85. See F. Randy Vogenberg & David Benjamin, The Medication-Use Process
and the Importance of Mastering Fundamentals, 36 P&T 651, 652 (2011).
86. See id. (describing the medication-use process as a “multistep process in
which a drug travels from the pharmacy to the patient [that] consists of (1) prescribing, (2) transcribing and documenting, (3) dispensing, (4) administering, and
(5) monitoring”).
87. 49 PA. CODE § 16.92(b)(8) (West 2020) (stating that the prescriber must
follow the standards of practice in addition for prescribing a medication and properly document the indication for the medication in the patient’s medical record).
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a controlled substance, the prescriber must also check the PDMP to
screen for abuse, misuse, or diversion.88 A pharmacist receives the
prescription and determines whether the prescription is valid and
contains all necessary components on its face.89 A pharmacist then
uses his professional judgment to determine if the medication will
likely be safe and effective for the patient.90 Pharmacists often do
this by conducting a drug-drug interaction and allergy check on a
patient’s prescription profile.91 At any step, the pharmacist must
alert the prescriber to any issues that would prohibit the pharmacist
from dispensing the medication, either due to the law or a pharmacist’s professional judgment.92
The pharmacist, as indicated earlier, also has a duty to determine if the prescription is likely to be diverted, misused, or abused.
This is the point at which a pharmacist would query and enter information into the PDMP.93 However, how and when the PDMP is
used depends on the pharmacy setting. In a community pharmacy,
the pharmacist or designee94 must check the PDMP and comply
with state law when determining whether to fill or refill a controlled
substance.95 In a hospital, when the patient is in observation status,
the pharmacist may access the PDMP; but when the patient is in
inpatient status, the pharmacist may not access the PDMP.96 This
disparity in patient status means that there is only one check by the
physician before a patient receives a controlled substance. The situ88. Act of Oct. 27, 2014, No. 191, 2014 Pa. Laws 191 § 5(viii)(A).
89. For a list of necessary components, see 49 PA. CODE § 27.18 (West 2020).
90. Id. § 27.18(m).
91. See The Pharmacist’s Role in Medication Safety, AGENCY FOR HEALTHCARE RSCH. & QUALITY, https://bit.ly/2ZdxfUT [https://perma.cc/UE2R-RR8E]
(last updated Sept. 7, 2019) (stating the correct medication use involves screening a
patient’s age, medical condition, physiologic status, and allergies to determine if a
prescription is appropriate to dispense).
92. See 49 PA. CODE § 27.18 (stating “if necessary the pharmacist shall attempt to discuss the decision with the prescriber); see also Riff v. Morgan Pharmacy, 508 A.2d 1247, 1251–52 (Pa. Super. 1986) (determining that a pharmacist is a
professional and has a legal duty to exercise due care and diligence in the performance of its professional duties and qualifying a pharmacy as “no more than a warehouse for drugs and that a pharmacists has no more responsibility than a shipping
clerk who must dutifully and unquestioningly obey the written orders of omniscient
physicians” as a disregard for a pharmacist’s professional duty).
93. See Act of Oct. 27, 2014, No. 191, 2014 Pa. Laws 191; 49 PA. CODE
§ 27.18(c).
94. See 2014 Pa. Laws 191 (permitting a pharmacist to appoint a designee,
such as a pharmacy technician or pharmacy intern, to query the system on his
behalf).
95. Id.
96. Act of Nov. 2, 2016, 2016 Pa. Laws 124.
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ation is worse in the emergency room when a pharmacist may not
access the PDMP and only the prescriber may do so.97
D. The ABC-MAP Act and the SEP Act
1. History and Impact of Pennsylvania’s PDMP
A PDMP is a state-specific program used to monitor controlled
substance prescriptions and the dispensing of controlled substances.98 The Pennsylvania Department of Health administers
Pennsylvania’s PDMP.99 The General Assembly created Pennsylvania’s first PDMP in 1972 to collect data on PDMP usage and
required pharmacies to send reports to Pennsylvania’s Office of Attorney General.100 The law was limited in scope because the PDMP
monitored only Schedule II prescription usage, and pharmacists
and physicians could not access the data within the system.101 Additionally, the reports were paper, and they were submitted only
monthly, which prohibited any practicable usage of the system by a
pharmacist—if he even had access.102 The Pennsylvania legislature
dramatically updated Pennsylvania’s PDMP law in 2014 with the
passage of the ABC-MAP Act, which modernized Pennsylvania’s
PDMP by getting the PDMP up to speed with the digital age by
making the PDMP accessible online, including pharmacists and
prescribers in curbing the opioid epidemic by granting them access
to the database103 and allowing states to be eligible for federal
grants by sharing the data with federal law enforcement.104
Despite PDMPs’ presence in 49 states and implementation in
Pennsylvania for decades,105 the public has scrutinized PDMPs for
two reasons: violations of privacy and due process.106 Pennsylvania, like most states, requires pharmacists to transmit data to
the state with personally identifiable information regarding con97. 2016 Pa. Laws 122 § 5 (requiring only a health care practitioner, not a
dispenser, to query the system in the emergency room department to determine if
the patient is receiving an opioid from another practitioner).
98. See Lynn S. Mirigian et al., The Pennsylvania Prescription Drug Monitoring Program, 20 Commonwealth 138 (2018).
99. See Act of Oct. 27, 2014, No. 191, 2014 Pa. Laws 191 § 4(a).
100. See Mirigian, supra note 98, at 139.
101. See id.
102. See id.
103. 2014 Pa. Laws 191 § 2.
104. 42 U.S.C. § 290ee-3 (2020) (offering federal grants to states to implement
PDMPs).
105. See Mirigian, supra note 98, at 139.
106. See Reem Blaik, Prescriptions at A Price: America’s Opioid Crisis and
the Increasing Toll on Drug Record Privacy, 21 VAND. J. ENT. & TECH. L. 277,
306–08 (2018).
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trolled substances that pharmacists have dispensed to a patient.107
Typically, only the pharmacist, physician, patient, law enforcement,
and payer would have this type of information.108
Even in light of these concerns, PDMPs have largely remained
intact, including third-party access to prescription information.109
While PDMPs are not expressly included in the Health Insurance
Portability and Accountability Act (HIPAA), those who access the
information are subject to HIPAA.110 Prescribers and pharmacists
have a duty and an incentive to protect their license to use the
PDMP for only patient care and not in violations of privacy or security rules of HIPAA.111
2. ABC-MAP Act
The ABC-MAP Act has three purposes, as articulated in Section 1 of the Act.112 The first purpose was to “increase quality of
patient care by giving . . . dispensers access to a patient’s prescription medication history through an electronic system that will alert
medical professionals to potential dangers for purposes of making
treatment determinations.”113 This first purpose is explicitly directed at pharmacists. The second purpose is to help patients “have
a thorough and easily obtainable record of their prescriptions for
purposes of making educated and thoughtful health care decisions.”114 This explicitly references a patient’s rights under the
PDMP program. The third purpose is to “[a]id regulatory and law
enforcement agencies in the detection and prevention of fraud,
drug abuse and in the criminal diversion of controlled sub107. 2014 Pa. Laws 191 § 7.
108. See Covered Entities and Business Associates, U.S. DEPT. HEALTH &
HUM. SERVS. (last updated June 16, 2017), https://bit.ly/2SiLBlt [https://perma.cc/
TAN4-PQ3J].
109. See generally Oregon Prescription Drug Monitoring Program v. U.S.
DEA, 860 F.3d 1228 (9th Cir. 2017) (permitting a PDMP administered by the Oregon Department of Health to transmit data to the DEA. Proponents of health
privacy have argued that sharing opioid prescribing and dispensing information
with others outside of the privity of the medication-use process is a violation of
one’s privacy, especially when shared with law enforcement. Despite the spillage of
information, anyone who has access to the PDMP’s information is required to safeguard that information).
110. See Stephen P. Wood, Prescription Monitoring Programs: HIPAA,
Cybersecurity and Privacy, HARVARD LAW BILL OF HEALTH (Jun. 17, 2018),
https://bit.ly/3e0FhI5 [https://perma.cc/SV95-C3Q6].
111. See id.
112. Act of Oct. 27, 2014, No. 191, 2014 Pa. Laws 191 § 1.
113. See 2014 Pa. Laws 191 § 2; see also id. § 3 (whereby a Pennsylvania-licensed pharmacist is a dispenser, stating “[a] person lawfully authorized to dispense in this Commonwealth . . .”).
114. See 2014 Pa. Laws 191 § 2.
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stances.”115 This clearly refers to law enforcement’s ability to collect data and coordinate efforts to pursue fraud, waste, abuse, and
diversion.
The Pennsylvania General Assembly modernized Pennsylvania’s PDMP by expanding monitoring to Schedules III, IV,
and V.116 In addition, prescribers and pharmacists now have realtime access to the system as well as statutory requirements to query
the system during the course of each respective practice.117 In a
national survey of states that had electronic PDMPs in which
prescribers and pharmacists could access the system, researchers
observed an average reduction of 1.12 opioid-related deaths per
100,000 people per year.118 In Pennsylvania, specifically, there was
an 89 percent reduction in the number of patients who saw more
than 5 prescribers and more than 5 dispensers or pharmacies in a 3month period for Schedule II substances.119
The ABC-MAP Act defines a dispenser as “a person lawfully
authorized to dispense in this Commonwealth” but excludes “a licensed health care facility that distributes the controlled substance
for the purpose of administration in the licensed care facility.”120
The Act classifies a pharmacist as a dispenser and a hospital as an
example of a licensed health care facility.121 Section 7 of the Act
outlines the information that a pharmacist must submit before dispensing a controlled substance and permits a pharmacist to designate other pharmacy employees to access the system, as permitted
by the Board of Pharmacy.122 Section 9 of the Act lays out the
limitations for all users of the system.123 A pharmacist or designee,
“may query the system for a current patient to whom the dispenser
is dispensing or considering dispensing any controlled substance.”124 This language gave the pharmacists the option to query
115. Id.
116. See Mirigian, supra note 98, at 144.
117. See Act of Nov. 2, 2016, 2016 Pa. Laws 124 § 7(c) (stating “[a] dispenser
or pharmacy shall submit all information . . . no later than the close of the subsequent business day after dispensing a controlled substance”).
118. Stephen W. Patrick et al., Implementation of Prescription Drug Monitoring Programs Associated with Reductions in Opioid-Related Death Rates, 35 Health
Affairs 1324, 1328 (2016).
119. See Mirigian, supra note 98, at 142 (citing communication with the Pennsylvania Department of Health Prescription Drug Monitoring Program office).
120. Act of Oct. 27, 2014, No. 191, 2014 Pa. Laws 191.
121. See 2014 Pa. Laws 191 § 3; see also Healthcare Facilities and Licensing,
PA. DEPT. HEALTH, https://bit.ly/2Q9qa5i [https://perma.cc/W3RR-ZRPM] (last
visited Dec. 4, 2020).
122. 2014 Pa. Laws 191 § 7.
123. Id. § 9.
124. Id. § 9(b)(2).
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the system.125 The 2016 Amendments of the ABC-MAP Act
changed the dispenser’s duties and merged the content of Sections 7
and 9.126
The new language states, “[A] dispenser shall query the system,” and it created an affirmative statutory duty of a pharmacist
during the medication-use process.127 Updates of the PDMP in real
time now occur as a result of the amendment because a dispenser
must enter data regarding dispensing the medication by end of business day.128 In addition to these new requirements, the amendment
instructs the Board of Pharmacy to require all dispensers to register
with the program.129 State law also says the following:
[A] dispenser shall query the system before dispensing an opioid
drug product or a benzodiazepine described to a patient if any of
the following apply: (i) The patient is a new patient of the dispenser. (ii) The patient pays cash when they have insurance. (iii)
The patient requests a refill early. (iv) The patient is getting
opioid drug products or benzodiazepines from more than one
prescriber.130

It is not a violation of a patient’s privacy rights for pharmacists to
check before filing a prescription for a current patient or in consideration of dispensing a controlled substance; however, when a pharmacist does this, he assumes a statutory duty.131 It is worth noting
that the PDMP selectively screens pharmacists from seeing whether
a patient is on opioids used to treat opioid use disorder, which complicates the pharmacist’s duty to screen a patient’s profile for drug
interactions.132 There are exceptions to this statutory duty such
that
[a] dispenser who, in the exercise of sound clinical judgment,
does not believe that a patient is abusing or diverting controlled
substances shall not be in violation of this act for not seeking or
obtaining information from the system prior to prescribing or dispensing so long as the prescriber or dispenser is otherwise in
compliance.133
125. Id.
126. Act of Nov. 2, 2016, 2016 Pa. Laws 124.
127. Id. § 7(e).
128. Id. (permitting a pharmacist to access more information about the dispensing history of a medication as well as increasing the pharmacist’s ability to
comply with the Pharmacy Act).
129. See Act of Nov. 2, 2016, 2016 Pa. Laws 124 § 5(5)(xvi).
130. Id. § 7(e)(1)(i).
131. See 35 PA. STAT. AND CONS. STAT. § 872.9; see also 2016 Pa. Laws 124.
132. Act of Oct. 27, 2014, No. 191, 2014 Pa. Laws 191.
133. 35 PA. STAT. AND CONS. STAT. § 872.8 (West 2020).
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The ABC-MAP Act contains provisions addressing unlawful acts,
including criminal liability, administrative liability through the
Board of Pharmacy, and a cause of action for civil liability.134 A
pharmacist commits a misdemeanor of the first degree if he knowingly or intentionally obtains or attempts to obtain patient information outside of the requirements during the medication-use process
to verify legitimate controlled substance dispensing.135 Additionally, a pharmacist who knowingly or intentionally “releases, sells,
transfers or otherwise makes available” or attempts to release, sell,
transfer or otherwise make available information from the PDMP
commits a third degree felony.136 Unauthorized use of the PDMP
or failure to follow the requirements can subject a pharmacist to
sanctions imposed by the Pennsylvania Board of Pharmacy and the
pharmacist’s employer.137 The civil liability provision is the most
contentious because it states that “knowing, intentional and negligent release or use of information from the system shall be subject
to a civil penalty,” and “other civil penalties shall be assessed in
accordance with department regulations.”138 Information in the
PDMP is protected healthcare information (“PHI”) under
HIPAA.139 HIPAA allows a patient to sue a pharmacist who improperly accesses his PHI if the violation occurred as a result of
professional malpractice.140
The Pennsylvania courts have developed case law to determine
when a pharmacist did or did not breach his duty of care. In Forish
v. Paul,141 the court refused to find a cause of action against pharmacists under professional malpractice or the implied warranty of
merchantability because “[t]o hold a pharmacist accountable for
monitoring use makes little practical sense—a patient could have
prescriptions filled at a number of different pharmacies, rendering
any attempt at comprehensive record-keeping virtually impossible
absent some type of state-wide regulatory scheme.”142 Additionally, because the Board of Pharmacy regulates pharmacies and
pharmacists, the court was “precluded from imposing duties in addition to those which the legislative branch has chosen to set
134.
135.
136.
137.
138.
139.
140.

2014 Pa. Laws 191 § 7.
Id. § 10(a)(1).
Id. § 10(a)(2).
Id. § 10(e).
Id. § 10(c).
42 U.S.C. § 17935.
Erica Lindsay, Can a Patient Sue a Pharmacist for Violating HIPAA?,
PHARMACY TIMES (Nov. 12, 2019), https://bit.ly/2QavXra [https://perma.cc/V4RE2LGU].
141. Forish v. Paul, 2 Pa. D. & C.4th 413 (C.P. 1989).
142. Id. at 416–17.
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forth.”143 This case was decided decades before the creation of the
current electronic PDMP, which established a state-wide regulatory
scheme that courts can now view as a duty imposed on pharmacists.
Prescribers also have a duty to check the system before prescribing, and in most instances, a controlled substance prescription
requires both a prescriber and pharmacist query.144 However, in
some instances, the law requires only the prescriber to query the
system before dispensing and does not permit the pharmacist to do
so.145 In particular circumstances, a pharmacist might end up dispensing lethal drugs because he does not have access to the system
and must rely on the prescriber’s having done so under this new
Pennsylvania law.146
3. The SEP Act
The Safe Emergency Prescribing Act is another piece of legislation that modified the duties of physicians and pharmacists—but
in the emergency room setting.147 Despite progress to reinforce the
need for a pharmacist to access the PDMP in executing his professional judgment in dispensing, the SEP law interferes with the
pharmacist’s role in the medication-use process.148 A pharmacist
cannot access the PDMP in the emergency room setting before dispensing a controlled substance.149 Under this new law, a dispensed
controlled substance in the emergency room that harms a patient
may not put the pharmacist at legal fault but may violate the pharmacist’s oath or contradict his professional judgment in the medication-use process. The heart of the issue is the conflict between the
SEP and ABC-MAP Acts and the pharmacist’s role in the medication-use process— if a pharmacist accessed the PDMP, would the
pharmacist be subject to state tort and federal medical privacy
claims? Could the pharmacist undergo disciplinary actions? The
profession has endured by protecting patients and maintaining respect as a profession in society. This analysis will explore why the
143. Id.
144. Act of Oct. 27, 2014, No. 191, 2014 Pa. Laws 191.
145. Id.
146. 2016 Pa. Laws 122.
147. Id.
148. 2014 Pa. Laws 191; SCOTT GIBERSON, SHERRI YODER, & MICHAEL P.
LEE, IMPROVING PATIENT AND HEALTH SYSTEM OUTCOMES THROUGH ADVANCED PHARMACY PRACTICE 12 (2011) (explaining that pharmacists have embraced expanded patient care roles in the emergency setting and that clinical
pharmacists in managing drug treatment may reduce health care costs and improve
the quality of care).
149. 2016 Pa. Laws 122.
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SEP ACT and the ABC-MAP Act are unnecessarily restrictive and
the issues that it has created for pharmacists in the Commonwealth.
III. ANALYSIS
A. Liability for a Pharmacist Accessing the PDMP in the
Emergency Room Setting Under the ABC-MAP Act and
the SEP Act
If a pharmacist accessed the PDMP to dispense a controlled
substance to a patient in the emergency room in good faith while
exercising professional judgment, he would be in violation of the
SEP Act and the ABC-MAP Act.150 In this instance, the pharmacist would not have committed a felony, but because the PDMP
access is unauthorized, he is subject to civil liability and administrative liability.151 The pharmacist is in a difficult situation, especially
if he suspects that the patient may be at risk to misuse, abuse, or
divert the medication.152
Prescribers have no obligation to check the PDMP for patients
who enter the emergency room.153 This lax protocol heightens the
burden on the pharmacist to decide whether it is better to act in the
best interests of protecting the patient in the normal course of the
medication-use process or to comply with the law. The law forces
the pharmacist to rely on the physician’s choice to query.154 Even if
it may be in the best interest of the patient’s health and safety for
the pharmacist to query, doing so may result in criminal, civil, and
administrative liability and adverse employment actions.155
1. Criminal and Civil Liability
Pharmacists are subject to state laws and regulations in the
normal course of practice, and they are subject to federal law and
regulations when handling PHI and controlled substances.156 The
150. Act of Oct. 27, 2014, No. 191, 2014 Pa. Laws 191; 2016 Pa. Laws 122.
151. 2014 Pa. Laws 191 §§ 10(a), (c).
152. See 49 PA. CODE § 27.18 (2019).
153. See Questions and Answers (Q&A), PA. DEPT. HEALTH, https://bit.ly/
34Qjo7U [https://perma.cc/6SBA-HFUK] (last visited Dec. 4, 2020) (stating
“[c]hecking the PDMP is not required for any medication provided to a patient in
the course of treatment while undergoing care in an emergency department. This
exception does not apply to patient undergoing care in urgent care centers or when
in observation status in a health care facility”).
154. Id.
155. See infra Part III.A.1.–2.
156. See supra Part II.B.1; 49 PA. CODE. § 27.18 (2020); 63 PA. STAT. AND
CONS. STAT. § 390 (stating uses and disclosures for which an authorization or opportunity to agree or object is not required); 45 C.F.R. § 164.512(a) (2020); 21
U.S.C. § 812 (2020).
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less regulated area is the use of professional judgment in the medication-use process, which is deferential to a pharmacist’s training,
knowledge, principles in the oath of a pharmacist, and the profession’s use of clinical practice guidelines.157 Regulation by the profession’s standards grants a pharmacist freedom to practice in the
best interest of the patient’s unique situation without fear of having
to follow a law created by non-pharmacists for determining how to
treat patients.158
Recall the young woman who passed away from an unintentional overdose; this serves as a tragic example of a case in which
the ABC-MAP Act and SEP Act could directly result in worsened
patient care by hampering the pharmacist’s professional judgment.
The pharmacist is in a very difficult situation when he receives the
medication order in this scenario because when verifying a medication order for an opioid or a benzodiazepine in the emergency
room, these laws blind the pharmacist to information that would
otherwise be available to him in other clinical settings—such as the
outpatient setting.159 On one hand, he could potentially violate his
oath and ignore currently accepted clinical practice guidelines and
his extensive training to comply with the law.160 On the other hand,
the pharmacist could query the patient’s name and date of birth in
the PDMP to find an objective medication history and alert the prescriber who may or may not have queried the PDMP himself.161 In
the latter case, the young woman may have survived but potentially
at the expense of the pharmacist’s license.
The Pennsylvania General Assembly expressed that it did not
intend to regulate the medicine and pharmacy professions, but that
is exactly what it did with the passage of the ABC-MAP and SEP
Acts.162 Under the ABC-MEP Act, which incorporates the SEP
Act, the state could charge the pharmacist with a misdemeanor.163
157. 49 PA. CODE § 27.18 (2020); 63 PA. STAT. AND CONS. STAT. § 390-3; See
Oath, supra note 64.
158. See Oath, supra note 64.
159. 2016 Pa. Laws 124; 35 PA. STAT. AND CONS. STAT. § 873.5.
160. See Oath, supra note 64; CTRS. FOR DISEASE CONTROL & PREVENTION,
CDC GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN (2016); see also
65 MORBIDITY & MORTALITY WEEKLY REPORTS: RECOMMENDATIONS AND REPORTS 1, 1–50 (2016).
161. 2016 Pa. Laws 122 § 5 (mandating that only a prescriber has the authority to query the PDMP). The liability is solely on the prescriber unless there exists
an issue on the face of the prescription or in issues of adulteration or misbranding.
See, e.g., Makripodis v. Merrell-Dow Pharm., 523 A.2d 374, 375 (Pa. Super. 1987);
Forish v. Paul, 2 Pa. D. & C.4th 413, 417 (C.P. 1989).
162. Pa. Representative Pamela A. DeLissio Speech, Pennsylvania General
Assembly, PA. LEGIS. J. HOUSE 1447 (June 23, 2016).
163. 2014 Pa. Laws 191 § 10(a)(1).
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A less likely but possible additional claim against the pharmacist is
that the pharmacist mishandled PHI by inquiring into the young
woman’s medical history.164 The PDMP inquiry constitutes an invasion of privacy, and the hospital, as a covered entity, could be
held liable for a privacy breach.165 The hospital could also take adverse employment action against the pharmacist.166
2. Administrative Liability
The Pennsylvania Board of Pharmacy may initiate disciplinary
proceedings against the pharmacist and suspend or revoke the
pharmacist’s license to practice in the Commonwealth.167 Disciplinary action in one state is often mandatory reporting to other states
in which the pharmacist holds a license to practice.168 Additionally,
if the pharmacist attempts to obtain licensure in a new state, most
states require him to report the status of his license in other states,
including if any disciplinary actions are pending or have taken
place.169 A pharmacist cannot practice without a license.170 An attempt to protect the patient from a drug-drug interaction, a pillar of
the oath of a pharmacist in the use of his professional judgment,
could cost him his license to practice.171
B. The ABC-MAP Act and SEP Act Should be Amended to
Protect Patients and Pharmacists
1. Statutory Changes
The Pennsylvania General Assembly should amend the SEP
Act and the ABC-MAP Act to better reflect the purpose of the
164. 45 C.F.R. § 164.512(a) (2019).
165. Id. § 164.506 (stating “whereby no authorization to access PHI from the
patient by the prescriber is necessary, the pharmacist may not be privy to that
information if state law does not permit the dispenser to know that information
under § 164.506(c)(5))”.
166. Id. § 164.306 (stating “whereby the hospital must conduct an inquiry into
the HIPAA violation and may take action to restrict future breaches, including up
to termination of the offending employee according to hospital policies and employment contracts”).
167. 63 PA. STAT. AND CONS. STAT. §§ 390(5), (7) (2019); see generally Gaynor v. Commonwealth, State Bd. of Pharmacy, 513 A.2d 521, 524 (Pa. Commw. Ct.
1986) (stating the Board of Pharmacy may discipline a pharmacist absent any criminal or civil liability).
168. Boards, NABP Examine Concurrent Sister-State Disciplinary Actions, 47
INNOVATIONS (Nat’l Ass’n Bds. Pharmacy, Mount Prospect, IL), Oct. 2018, at
10–12.
169. Id.
170. 63 P.S. § 390(3)(h) (2019).
171. See Oath, supra note 64; see also Vogenberg, supra note 85, at 651–52.
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ABC-MAP Act.172 The SEP Act Section 5 states that only the prescribing health care practitioner shall query the PDMP to determine if a patient is under treatment with an opioid drug product.173
The prescribing health care practitioner does not have to check the
PDMP before administering a medication in the emergency department.174 This requirement limits who can check the PDMP and the
purpose for checking the PDMP.175 First, the law should include
dispensing health care practitioners in addition to prescribing health
care practitioners as people who must query the PDMP to determine whether a patient may be under treatment with an opioid
drug product. This amendment would better reflect clinical practice guidelines and the pharmacist’s role in the medication-use process, as well as provide a double check that already exists in other
pharmacy settings.176 Pharmacists are trained and qualified to assess a patient for drug interactions, more so than the pharmacist’s
physician counterpart, and a pharmacist’s duty to provide safe and
effective treatment is burdened when essential resources, such as
the PDMP, are inaccessible. Second, the purpose of the query
should extend beyond the suspected use of an opioid product to
include benzodiazepines. While opioids frequently overshadow
benzodiazepines, the latter are commonly responsible for overdose
deaths, especially in combination with opioids.177 Finally, the Pennsylvania General Assembly should extend the law to apply to medications provided to a patient in the course of treatment while
172. Act of Oct. 27, 2014, No. 191, 2014 Pa. Laws 191; supra note 50.
173. 2016 Pa. Laws 122(5).
174. Id.
175. Id.
176. See Vogenberg, supra note 85, at 651–52. See generally Prescribing
Guidelines for Pennsylvania: Opioid Dispensing Guidelines, PA. DEPT. HEALTH
(Jan. 14, 2016), https://bit.ly/36nPYA4 [https://perma.cc/TQL3-85AQ]; Prescribing
Guidelines for Pennsylvania: Non-Cancer Pain Guidelines, PA. DEPT. HEALTH
(June 11, 2018), https://bit.ly/36mLcmx [https://perma.cc/Y5F7-FPNC]; Prescribing
Guidelines for Pennsylvania: Safe Prescribing Benzodiazepines for Acute Treatment of Anxiety & Insomnia, PA. DEPT. HEALTH (May 15, 2017), https://bit.ly/
34jwIlC [https://perma.cc/FV6V-R6KN] (describing the appropriate indications
and dosing for opioids and benzodiazepines for pain, anxiety, and insomnia, as well
as best practices for curbing misuse, abuse, and diversion).
177. See DRUG ENF’T AGENCY INTEL. PROGRAM—PHILA. FIELD DIV.,
DRUG-RELATED OVERDOSE DEATHS IN PA., 2018, 1 (2018), https://bit.ly/36qJxfF
[https://perma.cc/HH7W-3WGV] (reporting that twenty-eight percent of drug
overdose decedents had benzodiazepines in their systems); see also U.S. FOOD &
DRUG ADMIN., FDA News Release: FDA Requires Strong Warnings for Opioid
Analgesics, Prescription Opioid Cough Products, and Benzodiazepine Labeling
Related to Serious Risk and Death from Combined Use (Aug. 31, 2016), https://
bit.ly/38dlKQ5 [https://perma.cc/B8VU-WMBS] (warning prescribers and dispensers of the combination of benzodiazepines and opioids in patient due to the risk of
toxicity and central nervous system depression).
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undergoing care in an emergency department. Prescribers are already required to query the PDMP when writing a prescription in
the emergency department for patients to fill at an outpatient pharmacy.178 Why should this requirement not apply while undergoing
care in the emergency department? The obvious counterargument
is that the query takes time away from the patient to perform, but a
query can be done in seconds, and a prescriber’s designee can be
the one to query the PDMP.179 The Pennsylvania legislature does
not want to regulate the practices of pharmacy and medicine,180 but
it is already doing so by choosing to exclude a pharmacist’s essential
part of the medical-use process in the acute care setting.
The ABC-MAP Act Section 8(e) states that a licensing board
shall not discipline or hold civilly liable a dispenser who submits or
receives information in a PDMP inquiry under Section 7.181 However, this same immunity does not extend to the SEP Act. In conjunction with amending the SEP Act, the Pennsylvania General
Assembly should amend the immunity provision of the ABC-MAP
Act to protect pharmacists who query the PDMP in the emergency
room, as authorized by an amended SEP Act.182 This immunity
provision is vital to the implementation because even though a
pharmacist is granted the authority to access the PDMP, he may be
hesitant to do so if he thinks he could still be held liable.
2. Public Policy
A couple words added to a statute may be trivial, but they
could drastically affect patient outcomes for the better. They could
even save lives. The ABC-MAP Act and the SEP Act have made
some profound steps to address the opioid epidemic in the Commonwealth. Every two years, licensed pharmacists must perform
two hours of continuing education credits regarding pain management, identification of addiction, or dispensing opioids.183 Also, if a
prescriber identifies a patient in the PDMP query with suspicion for
178. Pa. Dept. of Health, PDMP Questions and Answers, https://bit.ly/
2S27TpV [https://perma.cc/P4B9-A6PL] (last visited Dec 4., 2020).
179. 2014 Pa. Laws 191 § 8(c) (indicating that the prescriber herself does not
need to perform the actual inquiry, and a designee, such as a registered nurse, is a
preferred surrogate for the prescriber).
180. See 2016 PA. LEGIS. J. HOUSE 1447 (describing a “dangerous precedent”
when the state legislature attempts to legislate how licensed health-care providers
practice, instead of allowing providers to defer to clinical practice guidelines and
training).
181. 2014 Pa. Laws 191 § 8(e).
182. 2014 Pa. Laws 191 § 8(e); Gabriel v. Giant Eagle, Inc., 124 F. Supp. 3d
550, 5642 (W.D. Pa. 2015).
183. 2016 Pa. Laws 124 § 9.1(a)(1).
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addiction in the emergency room, he is required to refer the patient
to treatment.184 Despite all the aforementioned evidence-based
methods to combat addiction and diversion that the state chose to
adopt, patient care still suffers when pharmacists are withheld from
accessing vital tools while dispensing opioids and
benzodiazepines.185
In Pennsylvania, a pharmacist has a duty to remedy inadequacies on the face of a physician’s prescriptions so that the prescription will be safe and effective for the patient and complies with
clinical practice guidelines.186 This duty includes a “duty to alert
the physician and make proper adjustments.”187 Failure to notice a
potentially lethal interaction between drugs on the face of a prescription falls within this duty.188 At the time the court decided
Forish v. Paul, there was “no authority in Pennsylvania which
would place on the profession the . . . [duty] . . . to be familiar with
the patient’s medical history and/or medical records.”189 The court
feared that this might blend two distinct professions, pharmacy and
medicine, and there was no authority to create such a duty.190 Since
Forish v. Paul was decided, the professions have developed, but
each has its own distinct roles in the medication-use process and
continue to require separate licenses, just as they have operated
since 1240 A.D.191 In addition, the ABC-MAP Act has created a
statutory duty that requires a pharmacist to now be familiar with a
patient’s medical records.192 A pharmacist’s training and expertise
means that he will use the PDMP information differently than a
184. 2016 Pa. Laws 122 § 4.
185. See Mirigian, supra note 98, at 142 (citing communication with the Pennsylvania Department of Health Prescription Drug Monitoring Program office).
186. Forish v. Paul, 2 Pa. D. & C.4th 413, 417 (C.P. 1989).
187. Id. at 416.
188. Id.
189. Id. at 417.
190. Id.
191. 63 P.S. §§ 390(3), 422(3) (2019) (creating the Pennsylvania State Board
of Medicine, which licenses and disciplines physicians and surgeons); HASTINGS
RASHDALL, THE UNIVERSITIES OF EUROPE IN THE MIDDLE AGES 85 (1895); James
J. Walsh, The Earliest Modern Law for the Regulation of the Practice of Medicine,
BULL. N.Y. ACAD. MED. 523–24 (1935).
192. Gabriel v. Giant Eagle, Inc., 124 F. Supp. 3d 550, 563 (W.D. Pa. 2015)
(quoting Forish, 2 Pa. D. & C.4th at 417) (“[t]o hold a pharmacist accountable for
monitoring use makes little practical sense—a patient could have prescriptions filled at a number of different pharmacies, rendering any attempt at comprehensive
record-keeping virtually impossible absent some type of state-wide regulatory
scheme” because the court could not “impose a duty that neither the legislature
nor the State Board of Pharmacy have imposed.”). Since Gabriel was decided, the
ABC-MAP Act was enacted, which created a duty from the legislature. See Act of
Nov. 2, 2016, 2016 Pa. Laws 124 § 7(e).
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prescriber would use the PDMP information at the dispensing stage
of the medication-use process.193
Since a Pennsylvania pharmacist now has access to the PDMP
before filling certain controlled substances in specific clinical settings, a new duty exists to query the PDMP.194 However, this duty
is hard to fulfill because of the roadblocks that inhibit pharmacist’s
access, especially in the emergency department setting.195 The
aforementioned changes to the ABC-MAP Act and the SEP Act
are necessary for pharmacists to remain the trusted and respected
members of society, and for improving the medication-use process
as a matter of public health policy.196
IV. CONCLUSION
This Comment has examined Pennsylvania’s PDMP statutes
for physicians and pharmacists.197 The two professions have developed over the millennia to develop professionals that are trained
and educated to handle distinct but interconnected roles in the
medication-use process.198 If each professional uses the PDMP
during his ordinary course of the medication-use process for prescribing and dispensing opioids and benzodiazepines, both the prescriber and the pharmacist will be able to provide safe and effective
treatment to patients.199 Physicians and pharmacists are expected
to follow common law and statutory duties of care in their respective professional capacities,200 but Pennsylvania’s PDMP statutes
do not provide the same level of assurance to both professions.201
In the emergency room setting in particular, pharmacists are
prohibited from accessing the PDMP in the ordinary course of verification and dispensing opioids and benzodiazepines.202 The pharmacist must rely on a physician’s query of the system.203 If a
193. See Vogenberg, supra note 85, at 651–52.
194. 2016 Pa. Laws 124; Act of Oct. 27, 2014, No. 191, 2014 Pa. Laws 191.
195. 2016 Pa. Laws 122.
196. See generally Honesty/Ethics in Professions, GALLUP, https://bit.ly/
34MSxKn [https://perma.cc/BHG5-URZK] (last visited Dec 4., 2020); Accreditation Standards, supra note 28; Kristy Malacos, PDMPs Can Help Curb the Opioid
Epidemic, PHARMACY TIMES (Nov. 20, 2019), https://bit.ly/2sVhfum [https://
perma.cc/WSJ4-QSY8] (describing how PDMP programs provide information to
quickly identify possible drug seeking behavior and inappropriate prescribing).
197. See supra Part II.D.
198. See supra Part II.A., II.C.
199. See supra Part II.C.
200. See supra Part II.A.2.
201. See supra Part III.
202. See supra Part II.D.3.
203. See supra Part II.D.2.
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pharmacist were to query the system to check for a drug-drug interaction in the emergency room setting, it would not rise to the level
of criminal activity under the laws, but it could potentially trigger
civil liability, administrative liability, and adverse employment action.204 Civil liability can stem from the PDMP statute itself for an
unauthorized query and may also rise to the level of a federal
HIPAA regulation violation.205 The State Board of Pharmacy has
the authority to administer disciplinary action to any pharmacist
that the state licenses.206 The employer, such as the hospital or
health system, can also suspend or terminate pharmacists that violate the PDMP laws.207
The pharmacist is not the only one who suffers from accessing
the PDMP in the course of the medication-use process. The public
also suffers a major disservice when pharmacists cannot act to the
full limit of their license and in accordance with evidence-based
practice in clinical practice guidelines.208 Pharmacists may be able
to detect a potential overdose, misuse, abuse, or drug diversion with
a simple PDMP query.209 As this Comment explains, the Pennsylvania legislature should amend ABC-MAP Act and the SEP Act
to provide pharmacists the same immunity as physicians and expand the PDMP query access so that pharmacists can effectively
practice pharmacy in Pennsylvania.210
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